Menière’s disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline—an observational study
暂无分享,去创建一个
[1] D. Rujescu,et al. Retraction Note to: Menière’s disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline—an observational study , 2018, Journal of Neurology.
[2] M. Burton,et al. Betahistine for Menière's disease or syndrome. , 2018, Cochrane Database of Systematic Reviews.
[3] L. Vécsei,et al. Monoamine Oxidase B Inhibitors in Parkinson's Disease. , 2017, CNS & neurological disorders drug targets.
[4] E. Ferrary,et al. Meniett device in meniere disease: Randomized, double‐blind, placebo‐controlled multicenter trial , 2017, The Laryngoscope.
[5] A. H. Hassan,et al. Transbuccal delivery of betahistine dihydrochloride from mucoadhesive tablets with a unidirectional drug flow: in vitro, ex vivo and in vivo evaluation , 2016, Drug design, development and therapy.
[6] P. Cayé-Thomasen,et al. Expression of histamine receptors in the human endolymphatic sac: the molecular rationale for betahistine use in Menieres disease , 2016, European Archives of Oto-Rhino-Laryngology.
[7] A. Schilder,et al. Betahistine for symptoms of vertigo. , 2016, The Cochrane database of systematic reviews.
[8] M. Strupp,et al. Efficacy and safety of betahistine treatment in patients with Meniere’s disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial) , 2016, British Medical Journal.
[9] F. Sallee,et al. Safety, tolerability and pharmacokinetics of 2‐pyridylacetic acid, a major metabolite of betahistine, in a phase 1 dose escalation study in subjects with ADHD , 2015, Biopharmaceutics & drug disposition.
[10] M. Strupp,et al. Diagnostic criteria for Menière's disease. , 2015, Journal of vestibular research : equilibrium & orientation.
[11] M. Strupp,et al. Histaminergic H3-Heteroreceptors as a Potential Mediator of Betahistine-Induced Increase in Cochlear Blood Flow , 2015, Audiology and Neurotology.
[12] W. Grolman,et al. Intratympanic gentamicin treatment for Ménière’s disease: a randomized, double-blind, placebo-controlled trial on dose efficacy - results of a prematurely ended study , 2014, Trials.
[13] Rania M. Hathout,et al. Transdermal delivery of betahistine hydrochloride using microemulsions: physical characterization, biophysical assessment, confocal imaging and permeation studies. , 2013, Colloids and surfaces. B, Biointerfaces.
[14] M. J. Derebery,et al. Oral Steroid Treatment for Hearing Improvement in Ménière’s Disease and Endolymphatic Hydrops , 2012, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.
[15] M. Strupp,et al. Betahistine Exerts a Dose-Dependent Effect on Cochlear Stria Vascularis Blood Flow in Guinea Pigs In Vivo , 2012, PloS one.
[16] B. Westerberg,et al. Intratympanic steroids for Ménière's disease or syndrome. , 2011, The Cochrane database of systematic reviews.
[17] K. Jahn,et al. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière’s disease: a case series , 2011, European Archives of Oto-Rhino-Laryngology.
[18] M. Paparella,et al. Meniere's disease , 2008, The Lancet.
[19] Adrian James,et al. Menière's disease. , 2007, BMJ clinical evidence.
[20] A. Burgess,et al. Diuretics for Ménière's disease or syndrome. , 2006, The Cochrane database of systematic reviews.
[21] A. Pfleiderer,et al. A national survey amongst UK otolaryngologists regarding the treatment of Ménière’s disease , 2005, The Journal of Laryngology & Otology.
[22] D. Zhong,et al. LC-MS-MS analysis of 2-pyridylacetic acid, a major metabolite of betahistine: application to a pharmacokinetic study in healthy volunteers , 2003, Xenobiotica; the fate of foreign compounds in biological systems.
[23] K. Sotaniemi,et al. Selegiline as initial treatment in de novo parkinsonian patients , 1992, Neurology.
[24] A. J. Lees,et al. Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ‘cheese effect’ , 1978, Psychopharmacology.
[25] A. Tobia,et al. The metabolism of betahistine in the rat. , 1974, Drug metabolism and disposition: the biological fate of chemicals.
[26] M. Lacour. Betahistine treatment in managing vertigo and improving vestibular compensation: clarification. , 2013, Journal of vestibular research : equilibrium & orientation.
[27] Anthony E. Lang,et al. Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.
[28] S. Shapiro. The surgery of Meniere's disease. , 1971, Eye, ear, nose & throat monthly.